These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26239646)

  • 1. Closing the drug lag for new drug submission and review in Japan: An industry perspective.
    Poirier AF
    Clin Pharmacol Ther; 2015 Nov; 98(5):486-8. PubMed ID: 26239646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Japan-Specific Key Regulatory Aspects for Development of New Biopharmaceutical Drug Products.
    Desai KG; Obayashi H; Colandene JD; Nesta DP
    J Pharm Sci; 2018 Jul; 107(7):1773-1786. PubMed ID: 29601839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent trends and success factors in reducing the lag time to approval of new drugs in Japan.
    Honig PK
    Clin Pharmacol Ther; 2014 May; 95(5):467-9. PubMed ID: 24747231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expediting patients' access to medicines by improving the predictability of drug development and the regulatory approval process.
    Liberti L; Breckenridge A; Eichler HG; Peterson R; McAuslane N; Walker S
    Clin Pharmacol Ther; 2010 Jan; 87(1):27-31. PubMed ID: 20019699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New paradigm for drug developments--from emerging market statistical perspective.
    Quan H; Chen X; Zhang J; Zhao PL
    Contemp Clin Trials; 2013 Nov; 36(2):697-703. PubMed ID: 23810938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delays in new drug applications in Japan and industrial R&D strategies.
    Hirai Y; Kinoshita H; Kusama M; Yasuda K; Sugiyama Y; Ono S
    Clin Pharmacol Ther; 2010 Feb; 87(2):212-8. PubMed ID: 19940847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2014 Jun; 30(5):371-2. PubMed ID: 24897062
    [No Abstract]   [Full Text] [Related]  

  • 8. Examining Manufacturing Readiness for Breakthrough Drug Development.
    Dye E; Sturgess A; Maheshwari G; May K; Ruegger C; Ramesh U; Tan H; Cockerill K; Groskoph J; Lacana E; Lee S; Miksinski SP
    AAPS PharmSciTech; 2016 Jun; 17(3):529-38. PubMed ID: 26608693
    [No Abstract]   [Full Text] [Related]  

  • 9. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage?
    Roman A
    Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322
    [No Abstract]   [Full Text] [Related]  

  • 10. Industry and regulatory performance in 2012: a year in review.
    Dowden HM; Jahn R; Catka T; Jonsson A; Michael E; Miwa Y; Zinkand W
    Clin Pharmacol Ther; 2013 Sep; 94(3):359-66. PubMed ID: 23657160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structured Benefit-risk assessment: a review of key publications and initiatives on frameworks and methodologies.
    Mt-Isa S; Ouwens M; Robert V; Gebel M; Schacht A; Hirsch I
    Pharm Stat; 2016 Jul; 15(4):324-32. PubMed ID: 25981683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond debacle and debate: developing solutions in drug safety.
    Ray A
    Nat Rev Drug Discov; 2009 Oct; 8(10):775-9. PubMed ID: 19763107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulatory challenges in the review of data from global clinical trials: the PMDA perspective.
    Asano K; Tanaka A; Sato T; Uyama Y
    Clin Pharmacol Ther; 2013 Aug; 94(2):195-8. PubMed ID: 23872835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
    [No Abstract]   [Full Text] [Related]  

  • 15. Quality, safety and efficacy of follow-on biologics in Japan.
    Yamaguchi T; Arato T
    Biologicals; 2011 Sep; 39(5):328-32. PubMed ID: 21890377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program.
    Galluppi GR; Brar S; Caro L; Chen Y; Frey N; Grimm HP; Rudd DJ; Li CC; Magee M; Mukherjee A; Nagao L; Purohit VS; Roy A; Salem AH; Sinha V; Suleiman AA; Taskar KS; Upreti VV; Weber B; Cook J
    Clin Pharmacol Ther; 2021 Nov; 110(5):1172-1175. PubMed ID: 33991429
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the success rates of new drug development in Japan and the lag behind the US.
    Hirai Y; Yamanaka Y; Kusama M; Ishibashi T; Sugiyama Y; Ono S
    Health Policy; 2012 Mar; 104(3):241-6. PubMed ID: 22172246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Affairs of the Heart: Innovation in Cardiovascular Research and Development.
    Honig P; Terzic A
    Clin Pharmacol Ther; 2017 Aug; 102(2):162-168. PubMed ID: 28718903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved therapeutic entities derived from known generics as an unexplored source of innovative drug products.
    Stegemann S; Klebovich I; Antal I; Blume HH; Magyar K; Németh G; Paál TL; Stumptner W; Thaler G; Van de Putte A; Shah VP
    Eur J Pharm Sci; 2011 Nov; 44(4):447-54. PubMed ID: 21968337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.